Sugi Predict

Sugi Predict / Compounds / SCHEMBL2108301

SCHEMBL2108301

SCHEMBL2108301

O=C(O)/C=C/C(=O)Oc1ccc([N+](=O)[O-])cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 2/20 0.54
▸ KMT2A Q03164 7/20 0.53
▸ MEN1 O00255 5/20 0.53
▸ ALDH1A1 P00352 4/20 0.53
▸ MAPT P10636 3/20 0.53
▸ TDP1 Q9NUW8 2/20 0.53
▸ KDM4E B2RXH2 1/20 0.53
▸ POLB P06746 1/20 0.53
▸ BCL9 O00512 1/20 0.51
▸ CTNNB1 P35222 1/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ PKM P14618 1/20 0.50
▸ SRD5A2 P31213 1/20 0.47
▸ CA1 P00915 1/20 0.46
▸ CA2 P00918 1/20 0.46
▸ CES2 O00748 1/20 0.46
▸ CES1 P23141 1/20 0.46
▸ MGLL Q99685 1/20 0.46
▸ NPC1 O15118 1/20 0.45
▸ MAPK1 P28482 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4296577 1.00 GAA (0.54) GAAKMT2AMEN1ALDH1A1MAPT
Ammonia Solution, Strong SCHEMBL9436280 0.98 GAA (0.53) GAAKMT2AMEN1ALDH1A1MAPT
Ammonia Solution, Strong SCHEMBL9436297 0.98 GAA (0.53) GAAKMT2AMEN1ALDH1A1MAPT
SCHEMBL4661270 0.93 GAA (0.61) GAAKMT2AMEN1ALDH1A1MAPT
SCHEMBL956911 0.93 GAA (0.61) GAAKMT2AMEN1ALDH1A1MAPT
SCHEMBL31119075 0.89 GAA (0.48) GAAKMT2AMEN1ALDH1A1MAPT
SCHEMBL17695797 0.85 GAA (0.57) GAAKMT2AMEN1ALDH1A1MAPT
SCHEMBL12858124 0.85 ACHE (0.60) GAAKMT2AMEN1ALDH1A1MAPT
SCHEMBL9359869 0.85 GAA (0.53) GAAKMT2AMEN1ALDH1A1MAPT
SCHEMBL11973529 0.83 GAA (0.58) GAAKMT2AALDH1A1MAPTBCL9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163269-B2 Bioactive stents for type II diabetics and methods for use thereof MEDIVAS, LLC 2012-04-24 — — US disclosed
CN-1984620-B Bioactive scaffolds for type II diabetic patients MEDIVAS LLC 2011-03-30 — — CN disclosed
US-7794706-B2 Based on biodegradable polymers containing polyester amide (PEA), polyester urethane (PEUR), and polyester urea (PEU) and immunostimulatory adjuvants; for delivery of compositions that bind to major histocompatibility complexes (MHC) alleles MEDIVAS, LLC (US) 2010-09-14 — — US disclosed
EP-2178541-A1 BIOABSORBABLE ELASTOMERIC ARTERIAL SUPPORT DEVICE AND METHODS OF USE Medivas, LLC (US) 2010-04-28 — — EP disclosed
EP-2170355-A1 BIOABSORBABLE ELASTOMERIC POLYMER NETWORKS, CROSS-LINKERS AND METHODS OF USE Medivas, LLC (US) 2010-04-07 — — EP disclosed
US-7649022-B2 Bioabsorbable elastomeric polymer networks, cross-linkers and methods of use MEDIVAS, LLC (US) 2010-01-19 — — US disclosed
US-20090253809-A1 BIOABSORBABLE ELASTOMERIC POLYMER NETWORKS, CROSS-LINKERS AND METHODS OF USE MEDIVAS, LLC (US) 2009-10-08 — — US disclosed
EP-1283872-B1 CATALYTICALLY ACTIVE PEPTIDES MODPRO AB (SE) 2009-10-07 — — EP disclosed
US-20090182119-A9 CATALYTICALLY ACTIVE PEPTIDES MODPRO AB (SE) 2009-07-16 — — US disclosed
US-7514222-B2 Site selective acylation MODPRO AB (SE) 2009-04-07 — — US disclosed
US-20060234291-A1 Site selective acylation MODPRO AB (SE) 2006-10-19 — — US disclosed
US-20060188469-A1 Vaccine delivery compositions and methods of use MEDIVAS, LLC (US) 2006-08-24 — — US disclosed
EP-0952980-B1 ACYL TRANSFER WITH STABILISED TRANSITION COMPLEX USING CATALYST WITH CATALYTIC IMIDAZOLE (E.G. HISTIDINE) FUNCTION MODPRO AB (SE) 2006-08-23 — — EP disclosed
WO-2006050091-A2 BIOACTIVE WOUND DRESSINGS AND IMPLANTABLE DEVICES AND METHODS OF USE MEDIVAS, LLC (US) 2006-05-11 — — WO disclosed
US-20050238689-A1 Bioactive stents for type II diabetics and methods for use thereof MEDIVAS, LLC (US) 2005-10-27 — — US disclosed
EP-1456226-A1 SITE SELECTIVE ACYLATION ModPro AB (SE) 2004-09-15 — — EP disclosed
WO-2003044042-A9 SITE SELECTIVE ACYLATION MODPRO AB (SE) 2004-04-22 — — WO disclosed
WO-2003044042-A1 SITE SELECTIVE ACYLATION MODPRO AB (SE) 2003-05-30 — — WO disclosed
EP-0952980-A1 ACYL TRANSFER WITH STABILISED TRANSITION COMPLEX USING CATALYST WITH CATALYTIC IMIDAZOLE (E.G. HISTIDINE) FUNCTION A+Science Invest AB (SE) 1999-11-03 — — EP disclosed
WO-1997043302-A1 ACYL TRANSFER WITH STABILISED TRANSITION COMPLEX USING CATALYST WITH CATALYTIC IMIDAZOLE (E.G. HISTIDINE) FUNCTION A+SCIENCE INVEST AB (SE) 1997-11-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050238689-A1 Bioactive stents for type II diabetics and methods for use thereof CD47, ITGB2, ITGA2 GAA 1741/4885KMT2A 2232/4885MEN1 3653/4885
US-20090253809-A1 BIOABSORBABLE ELASTOMERIC POLYMER NETWORKS, CROSS-LINKERS AND METHODS OF USE FAU, PEF1, APEH GAA 2551/4885KMT2A 2394/4885MEN1 3301/4885
US-20060188469-A1 Vaccine delivery compositions and methods of use PUF60, UACA, USP36 GAA 3386/4885KMT2A 2753/4885MEN1 946/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.